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Concise Report
High incidence of severe ischaemic complications in patients with
giant cell arteritis irrespective of platelet count and size, and
platelet inhibition
C. T. Berger1,2, M. Wolbers3, P. Meyer4, T. Daikeler1,5,* and C. Hess1,2,*
Objective. Vision loss and ischaemic stroke are feared complications in GCA. We investigated how platelet count and size and platelet
inhibition with ASA relate to ischaemic complications in patients with GCA.
Methods. Charts of patients with GCA were retrospectively analysed. Jaw claudication, amaurosis fugax, blurred vision, ischaemic stroke
and permanent visual loss were classified as ‘ischaemic events’; ischaemic stroke and permanent visual loss were sub-grouped as ‘severe
ischaemic events’. The incidence of ischaemia and the association to the pre-defined covariates age, fever, ESR, platelet count and size and
ASA treatment were assessed.
Results. Eighty-five patients (mean age 73 yrs, 60% women, 78% biopsy-proven) were included in the analysis. Of the 85 patients, 62 (73%)
presented with ischaemic events, 29/85 patients (34%) with severe ischaemic events. At the time of diagnosis 22/85 patients (26%) were
treated with ASA. Of these 22 patients, 15 (68%) presented with ischaemic events, 7/22 patients (32%) with severe ischaemic events.
In multivariate analysis, neither platelet count nor size or ASA treatment were significantly associated with ischaemic or severe ischaemic
events.
Conclusions. The incidence of severe ischaemic events in patients with GCA was high, irrespective of platelet count and size and
established ASA treatment.
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Introduction
GCA is the most frequent of the vasculitis syndromes, affecting
large arteries and being predominantly a disease of the elderly
[1]. Patients typically present with constitutional symptoms, head-
ache and a systemic inflammatory syndrome. Anterior ischaemic
optic neuropathy (AION) with consecutive vision loss and
ischaemic stroke are feared complications. Definite diagnosis
relies on the presence of typical histological features in the bio-
psy of an affected artery. Identifying patients at risk for severe
ischaemic events remains an unresolved issue. Older age, a low
systemic inflammatory response and signs of ischaemia in absence
of constitutional symptoms have all been suggested as indepen-
dent risk factors for ischaemic damage [2–7]. Recently, the histo-
pathological finding of occluding intima proliferation, and the
presence and number of giant cells have been suggested as
additional risk factors for ischaemic events [8, 9]. The pathogenic
role of platelet aggregation in the development of irreversible
ischaemic events in patients with GCA remains controversial
[10–13]. Here we investigated how (i) platelet count and size
[14] and (ii) established platelet inhibition with ASA are asso-
ciated with ischaemic complications in a cohort of 85 patients
with GCA.
Patients and methods
Study population, case definition and data collection
We conducted a retrospective chart analysis of patients with
GCA. The study was approved by the local ethical committee
(Basel, Switzerland). Patients were identified (i) via screening for
histological diagnoses of GCA on temporal artery biopsy (TAB)
between June 1997 and June 2007 at the Institute of Pathology of
the University of Basel and (ii) by performing a computerized
search for the diagnosis of GCA listed in demission letters issued
from January 2003 through January 2007 for inpatients at the
Department of Internal Medicine of the University Hospital
Basel. Cases identified by this search were included in the study if
they fulfilled53 ACR classification criteria [15]. Patients with <3
ACR criteria were included if on TAB histopathological features
of GCA were present (inflammation, destruction of the internal
elastic membrane, multinucleated giant cells) and additional firm
evidence for GCA existed (e.g. AION or findings consistent with
large vessel vasculitis on PET). Patients were excluded if data
mandatory for disease classification were missing, or TAB was
negative and <3 ACR criteria were present.
Definitions of the ACR were used to classify clinical signs and
symptoms. Weight loss of either >2 kg over 1 month preceding
diagnosis, or >10% of the total body weight within 6 months
preceding diagnosis was defined as being significant. As ‘ischaemic
events’ we defined jaw claudication, amaurosis fugax, blurred
vision in timely correlation to the diagnosis of GCA, AION and
ischaemic stroke occurring within 2 weeks of diagnosis. The latter
two (AION and ischaemic stroke) were sub-grouped as ‘severe
ischaemic events’. Normal values for ESR were defined as
<24mm in the first hour (<24mm/1 h), normal values for platelet
counts as 100–250 109/l. In all cases, a detailed chart review was
performed (Table 1). Mean platelet volumes (MPVs) were mea-
sured using routine flow cytometric analysis (ADVIA 120
analyser, Siemens, Zu¨rich, Switzerland). All available biopsies
were re-reviewed and graded in a blinded manner by a senior
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pathologist (P.M.). The degree of intimal proliferation-related
maximal stenosis was graded as follows: Grade 1: <50%, Grade 2:
50–75%, Grade 3: >75% and Grade 4: complete luminal
occlusion. The presence and number of giant cells was assessed
semi-quantitatively (0: absent, 1: rare, 2: medium, 3: numerous) [8, 9].
Statistical methods
The association between ischaemic events (all and severe) and
selected covariates was studied using simple and multiple logistic
regression analysis. The following covariates were pre-defined:
age, fever, ESR, platelet count, MPV and medication with ASA.
In addition, the covariates ‘grade intimal hyperplasia’ and ‘grade
of presence of giant cells’ were added to the model. Due to low
sample size, we fitted only one parameter corresponding to a
linear trend for ordinal covariates. Because of an almost perfect
association of the semi-quantitative grade and the absolute maxi-
mal number of giant cells present on a biopsy, only the asso-
ciations between the semi-quantitative grading and outcomes were
explored. For reasons of efficiency and to avoid potential bias, we
used multiple imputation of missing covariates for the multiple
logistic regression analysis. All analyses were performed using R
version 2.3.1 (R Foundation for Statistical Computing, Vienna,
Austria) [16]. Multiple imputations were performed with the
R package MICE [17].
Results
Screening histological data and demission letters we identified
a total of 104 patients with suspected or definite diagnosis of
GCA. Of these, 19 patients were excluded from analysis for the
following reasons: 11/19 did not match inclusion criteria (negative
TAB and ACR score 42) or had a more probable alternative
diagnosis (2 Takayasu arteritis, 1 PAN), and in 8/19 data sets
substantial portions of the clinical information (six patients) or
laboratory values (two patients) were missing. On the other hand,
one patient was included as ‘waiver’ despite fulfilling only two
ACR criteria and being negative on TAB (78-yr old male, PMR,
jaw claudication, ESR 68mm/1 h, PET studies compatible with
large-vessel vasculitis). MPV was missing for 18 of the 85 patients,
platelet counts for four, information on medication with ASA
for one patient, and for five patients biopsies were not available;
none of the other covariates were missing for any patient.
The clinical characteristics of the 85 patients included in this
study and an overview of their clinical presentation at the time
of diagnosis are summarized in Table 1. Intriguingly, at diag-
nosis 3/85 had an ESR <24mm/1 h (i.e. a normal ESR) without
prior treatment with corticosteroids. Two out of these three
experienced AION, pointing out the importance of not excluding
the possibility of GCA in patients presenting with normal
ESR if other findings argue for this diagnosis. However, in both
cases the distracting finding of a low ESR did not result in a
diagnostic delay. Characteristics of the patients with low ESR
without prior corticosteroid treatment are shown as
Supplementary Table 1, available as supplementary data at
Rheumatology Online.
Multiple regression analysis identified age as an indepen-
dent risk factor for severe ischaemic complications [adjusted odds
ratio (OR)¼ 2.72; 95% CI 1.26, 5.88; P¼ 0.01], and showed that
patients with fever (defined as a tympanal temperature >38.58C)
had a lower likelihood to present with any ischaemic event
(adjusted OR¼ 0.23; 95% CI 0.06, 0.91; P¼ 0.04) (Table 2). Jaw
claudication (Fisher’s exact test: P¼ 0.04), but not amaurosis
fugax (P¼ 1), was significantly associated with ‘severe ischaemic
events’ in univariate analyses.
The retrospective nature of our data hinders a meaningful
analysis of how the duration of jaw claudication and development
of severe ischaemia are related. The overall incidence of ischaemic
events was 73% (62/85 patients); the overall incidence of severe
ischaemic events was 34% (29/85 patients). At the time of
diagnosis, 22/85 patients (26%) were treated with ASA. In the
ASA-treated subgroup, the incidence of ischaemic events was 68%
(15/22 patients) and the incidence of severe ischaemic events
was 32% (7/22 patients). Platelet counts were >250 109/l in
73/85 patients (86%) and >400 109/l in 45/85 patients (53%).
Thrombopenia (platelet count <150 109/l) was observed in only
2/85 patients (2%). No significant association of ischaemic events
(all or severe) and platelet counts was detected (Table 2). Also, no
significant correlation between an increased MPV and the occur-
rence of ischaemic events (all or severe) was detected (Table 2
and Fig. 1).
Overall, in biopsy-positive patients a trend towards a higher
risk for ‘ischaemic events’ as well as for ‘severe ischaemic events’
was observed (56 vs 77%; unadjusted OR ¼ 2.64; 95% CI 0.84,
8.30; P¼ 0.10 and 19 vs 39%; unadjusted OR¼ 2.81; 95% CI 0.73,
10.85; P¼ 0.13, respectively). The associations of the histopatho-
logical findings and ischaemic events are shown in Table 2.
Assessing subgroups of ischaemic events, we found a significant
association only for ‘jaw claudication’ with both the grade of
arterial occlusion by intima proliferation (P¼ 0.01) and the extent
of the presence of giant cells (P¼ 0.046). Of note, TAB in both
patients with cerebral ischaemia showed >75% occlusion of the
temporal artery due to intimal proliferation and numerous giant
cells (Grade 3, maximal number of giant cells on a cross-section 5
and 8, respectively).
Discussion
The key finding of this study was a worrisome high incidence of
severe ischaemic events (AION and stroke) in GCA patients
treated with ASA—irrespective of their platelet count and size.
This observation was made in a well-characterized cohort of 85
TABLE 1. Baseline characteristics and clinical presentation of the study population
(N¼85)
Age, mean S.D. (range), yrs 738 (52–96)
Female gender, n (%) 51 (60)
ACR criteria, mean S.D. (range) 3.90.9 (2–5)
TAB, done, n (%) 82 (97)
Positive TAB (of all patients), n (%) 66 (78)
Hb, mean S.D. (range), g/l 12316 (85–164)
MPV, mean S.D. (range), fl 7.70.8 (6.1–9.5)
ESR, mean S.D. (range), mm/1 h 6828 (6–115)
Clinical symptoms at diagnosis, n (%)
Headaches 74 (87)
PMR 53 (62)
Jaw claudication 45 (53)
Pathological temporal artery 42 (49)
Weight loss 29 (34)
Permanent vision loss 27 (32)
Scalp tenderness 27 (32)
Fever 18 (21)
Blurred vision 11 (13)
Amaurosis fugax 9 (11)
Stroke 2 (2)
One or more CVRF present, n (%) 67 (87)
Treatment at diagnosis, n (%)
Prednisone 9 (11)
ASA 22 (26)
Oral anti-coagulation 7 (8)
Histopathological findings (N¼80)
Arterial lumen occlusion by intima hyperplasia, n (%)
<50% (Grade 1) 16 (20)
50–75% (Grade 2) 24 (30)
>75% (Grade 3) 32 (40)
100% (Grade 4) 8 (10)
Presence/frequency of giant cells, n (%)
Absent (Grade 0) 40 (50)
Rare (Grade 1) 26 (33)
Medium (Grade 2) 9 (11)
Numerous (Grade 3) 5 (6)
Hb: haemoglobin level, PTL: platelet count, CVRF: cardiovascular risk factors [i.e. arterial
hypertension, n¼ 60 (71%), diabetes mellitus type 2 n¼ 12 (14%), hypercholesterolaemia n¼ 17
(20%), smoking n¼ 16 (19%)].
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patients with GCA, which is to our knowledge the largest Swiss
GCA cohort reported to date. Patient characteristics were com-
parable with those reported by others, and accepted risk factors
for ischaemic events [‘all events’; fever (inverse relation) and
‘severe events’; age] were confirmed [2–6]. The high prevalence of
permanent visual loss observed in our cohort might relate to the
large percentage of patients referred to us from the Department of
Ophthalmology [2–6]. Of note, in multiple logistic regression
analyses, neither platelet count nor size nor ASA treatment was
found to be significantly associated with severe ischaemic events.
However, due to the low number of events, CIs were wide and do
not exclude clinically relevant effects of these factors.
Previous studies yielded conflicting results regarding the
correlation of platelet count, platelet inhibition and ischaemic
events [2, 4–7, 11, 18]. In line with our findings, Gonzalez-Gay
et al. [7]—reporting the largest as yet published GCA cohort
(n¼ 240)—found no difference in platelet counts of patients
with vs those without severe ischaemic events. As for platelet
inhibition it is noticeable that in the largest study that linked ASA
treatment to protection from ischaemic events [10], the percentage
of study participants treated with ASA was much higher than in
both the study by Gonzalez-Gay et al. and the herein reported
cohort. Differing patient populations thus might limit study
comparability. While it can, of course, be envisioned that specific
subgroups of GCA patients benefit from ASA (stratified, e.g., for
co-morbidities, genetic background, etc.) [5, 10], large and
prospectively designed cohorts are much needed to provide us
with more definite evidence.
The association of specific pathological changes with an
increased risk for permanent visual loss is a biological plausibility
[8, 9]. Our data fail to directly reproduce this association.
However, our finding of a statistical link between ‘jaw claudica-
tion’ and pathological changes, and the fact that ‘jaw claudication’
per se was a predictor of ‘severe ischaemic events’ (including
‘AION’), suggests that methodological rather than biological
issues account for this discrepancy. For example, the pool of
patients from which a study population is recruited (e.g.
ophthalmology referral centre vs internal medicine referral
centre) may not only impact the proportion of patients affected
by a given ischaemic complication, but also select for study
participants with inherently differing risk profiles.
In summary, our study clearly indicates that—with regards
to the risk of irreversible ischaemic events in patients newly
diagnosed with GCA—clinicians should make no assumptions
based on a patient’s status with regards to already established
platelet inhibition. Prospective studies are urgently needed to
thoroughly assess the role of platelet inhibition in patients
with GCA.
TABLE 2. Multiple logistic regression analysis of variables associated with any ischaemic events and severe ischaemic events
Unadjusteda OR (95% CI) P-value Adjustedb OR (95% CI) P-value
Ischaemic events
Covariate
Age (10 yr increments) 1.31 (0.74–2.31) 0.36 1.12 (0.60–2.09) 0.72
Fever 0.26 (0.09–0.79) 0.02 0.23 (0.06–0.91) 0.04
ESR (increments of 10 mm/1 h) 0.93 (0.77–1.11) 0.42 0.91 (0.73–1.14) 0.42
PTL (increments of 105/mm3) 1.11 (0.81–1.52) 0.52 1.20 (0.80–1.81) 0.39
MPV (fl) 1.04 (0.56–1.93) 0.91 0.80 (0.40–2.02) 0.80
ASA: yes 0.68 (0.23–1.99) 0.49 0.87 (0.25–3.08) 0.83
Intima proliferation (by þ1 grade) 1.80 (1.01–3.20) 0.04 1.22 (0.61–2.46) 0.57
Giant cells (by þ1 grade) 2.19 (1.03–4.66) 0.04 2.01 (0.87–4.65) 0.10
Severe ischaemic events
Covariate
Age (10 yr increments) 2.70 (1.38–5.29) 0.004 2.72 (1.26–5.88) 0.01
Fever 0.19 (0.04–0.87) 0.03 0.29 (0.05–1.82) 0.19
ESR (increments of 10 mm/1 h) 0.86 (0.72–1.01) 0.07 0.86 (0.70–1.06) 0.16
PTL (increments of 105/mm3) 0.92 (0.69–1.23) 0.57 1.13 (0.75–1.69) 0.56
MPV (fl) 1.70 (0.91–3.20) 0.10 1.32 (0.60–2.91) 0.50
ASA: yes 0.85 (0.30–2.39) 0.76 0.86 (0.25–2.96) 0.81
Intima proliferation (by þ1 grade) 1.43 (0.85–2.38) 0.17 1.41 (0.71–2.81) 0.32
Giant cells (by þ1 grade) 1.27 (0.77–2.11) 0.35 1.22 (0.62–2.39) 0.57
aBased on patients with non-missing data of the respective covariate only. bAdjusted for all other covariates, based on data from all patients using multiple imputation. PTL: platelet count;






























FIG. 1. Box plots of mean platelet volume in patients with GCA grouped according to the occurrence of ‘ischaemic events’ and ‘severe ischaemic events’. The MPV did not
significantly differ between GCA patients presenting with or without any ischaemic event (A) or with or without severe ischaemic events (B), respectively.
Rheumatology key messages
 Severe ischaemic events occur with high prevalence despite
established platelet inhibition.
 Neither platelet count nor size is strongly associated with the risk
of severe ischaemic events.
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